The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast

被引：4
作者：
Pandithar, Sneha [1 ]
Galke, Daniel [1 ]
Akume, Ahone [1 ]
Belyakov, Artem [1 ]
Lomonaco, Dominick [1 ]
Guerra, Amirah A. [1 ]
Park, Jay [1 ]
Reff, Olivia [1 ]
Jin, Kideok [1 ]
机构：
[1] Albany Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, 106 New Scotland Ave,BRB Room 105B, Albany, NY 12208 USA
来源：
MOLECULAR BIOLOGY REPORTS | 2024年 / 51卷 / 01期
基金：
美国国家卫生研究院;
关键词：
Breast cancer; Endocrine resistance; CXCL1; Fibroblast; ESTROGEN-RECEPTOR; LYMPHANGIOGENESIS; INHIBITION; MECHANISMS; EXPRESSION; TAMOXIFEN; ER;
D O I：
10.1007/s11033-023-09119-4
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
BackgroundER positive breast cancer is currently targeted using various endocrine therapies. Despite the proven therapeutic efficacy, resistance to the drug and reoccurrence of tumor appears to be a complication that many patients deal with. Molecular pathways underlying the development of resistance are being widely studied.Methods and resultsIn this study, using four established endocrine resistant breast cancer (ERBC) cell lines, we characterized CXCL1 as a secreted factor in crosstalk between ERBC cells and fibroblasts. Protein array revealed upregulation of CXCL1 and we confirmed the CXCL1 expression by real-time qRT-PCR and U-Plex assay. Co-culturing ERBC cells with fibroblasts enhanced the cell growth and migration compared to monoculture. The crosstalk of ERBC cells with fibroblasts significantly activates ERK/MAPK signaling pathway while reparixin, CXCR1/2 receptor inhibitor, attenuates the activity. Reparixin displayed the ERBC cell growth inhibition and the combination treatment with reparixin and CDK4/6 inhibitor (palbociclib and ribociclib) increased these inhibitory effect.ConclusionsTaken together, our study implicates CXCL1 as a critical role in ERBC growth and metastasis via crosstalk with fibroblast and cotargeting CXCR1/2 and CDK4/6 could potentially overcome endocrine resistant breast cancer.
引用
收藏
页数：12
相关论文
共 40 条
[1]   A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis [J].
Acharyya, Swarnali ;
Oskarsson, Thordur ;
Vanharanta, Sakari ;
Malladi, Srinivas ;
Kim, Juliet ;
Morris, Patrick G. ;
Manova-Todorova, Katia ;
Leversha, Margaret ;
Hogg, Nancy ;
Seshan, Venkatraman E. ;
Norton, Larry ;
Brogi, Edi ;
Massague, Joan .
CELL, 2012, 150 (01) :165-178
[2]   Elevation of CXCL1 indicates poor prognosis and radioresistance by inducing mesenchymal transition in glioblastoma [J].
Alafate, Wahafu ;
Li, Xiaodong ;
Zuo, Jie ;
Zhang, Hua ;
Xiang, Jianyang ;
Wu, Wei ;
Xie, Wanfu ;
Bai, Xiaobin ;
Wang, Maode ;
Wang, Jia .
CNS NEUROSCIENCE & THERAPEUTICS, 2020, 26 (04) :475-485
[3]   Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies [J].
Aldea, Mihaela ;
Andre, Fabrice ;
Marabelle, Aurelien ;
Dogan, Semih ;
Barlesi, Fabrice ;
Soria, Jean-Charles .
CANCER DISCOVERY, 2021, 11 (04) :874-899
[4]   Therapeutic Targeting of the Tumor Microenvironment [J].
Bejarano, Leire ;
Jordao, Marta J. C. ;
Joyce, Johanna A. .
CANCER DISCOVERY, 2021, 11 (04) :933-959
[5]   Functional diversity of cancer-associated fibroblasts in modulating drug resistance [J].
Bu, Luke ;
Baba, Hideo ;
Yasuda, Tadahito ;
Uchihara, Tomoyuki ;
Ishimoto, Takatsugu .
CANCER SCIENCE, 2020, 111 (10) :3468-3477
[6]   Clinical and therapeutic relevance of cancer-associated fibroblasts [J].
Chen, Yang ;
McAndrews, Kathleen M. ;
Kalluri, Raghu .
NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (12) :792-804
[7]  
Divella R, 2013, ANTICANCER RES, V33, P1491
[8]   Tumor Lymphangiogenesis as a Potential Therapeutic Target [J].
Duong, Tam ;
Koopman, Peter ;
Francois, Mathias .
JOURNAL OF ONCOLOGY, 2012, 2012
[9]   ESR1 mutations in breast cancer [J].
Dustin, Derek ;
Gu, Guowei ;
Fuqua, Suzanne A. W. .
CANCER, 2019, 125 (21) :3714-3728
[10]   Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies [J].
Fan, Weimin ;
Chang, Jinjia ;
Fu, Peifeng .
FUTURE MEDICINAL CHEMISTRY, 2015, 7 (12) :1511-1519
1234